Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis

被引:13
作者
Reuben, Jayne S. [1 ]
Dinh, Laura [1 ]
Lee, Jane [1 ]
Stateson, Jonathan [1 ]
Kamara, Harold [1 ]
Xiang, Lilin [1 ]
Opperman, Lynne A. [1 ]
机构
[1] Texas A&M Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX USA
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY | 2011年 / 111卷 / 02期
关键词
ENCAPSULATED DICHLOROMETHYLENE DIPHOSPHONATE; COLONY-STIMULATING FACTOR; IN-VITRO; MACROPHAGE DEPLETION; TYROSINE PHOSPHORYLATION; PROINFLAMMATORY CYTOKINES; INFLAMMATORY CYTOKINES; SELECTIVE DEPLETION; MEVALONATE PATHWAY; AVASCULAR NECROSIS;
D O I
10.1016/j.tripleo.2010.09.068
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective. This study tested the effects of bisphosphonates (BPs) on the suppressor of cytokine signaling 3 (SOCS3) protein in macrophages. SOCS3 has been shown to regulate cell differentiation and survival; however, its potential role in mediating the effects of BPs has not been explored. Study design. The cell viability of murine RAW 267.4 macrophages was assessed after culturing with control medium or media containing increasing concentrations of 2 BPs (ibandronate or clodronate) for 24, 48, and 72 hours. The phosphorylation status of signal transducer and activator of transcription 3 (STAT3) and the expression of SOCS3 protein levels were determined by Western blot analysis. Results. In control cultures, STAT3 phosphorylation and STAT3 and SOCS3 protein levels increased within 5 minutes after the addition of fresh medium. This increase was inhibited in cultures treated with both BPs. Macrophage cell viability also decreased after BP treatment. Conclusions. These data demonstrate that, in addition to their effects on macrophage viability, BPs can decrease STAT3 and SOCS3 expression, which are important modulators of immune responses and bone homeostasis. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:196-204)
引用
收藏
页码:196 / 204
页数:9
相关论文
共 80 条
[1]   Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties [J].
Aksoy, S ;
Abali, H ;
Dinçer, M ;
Kilickap, S ;
Güllü, I ;
Tekuzman, G .
MEDICAL HYPOTHESES, 2004, 62 (06) :942-944
[2]   Alendronate disturbs vesicular trafficking in osteoclasts [J].
Alakangas, A ;
Selander, K ;
Mulari, M ;
Halleen, J ;
Lehenkari, P ;
Mönkkönen, J ;
Salo, J ;
Väänänen, K .
CALCIFIED TISSUE INTERNATIONAL, 2002, 70 (01) :40-47
[3]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[4]   Activation of downstream signals by the long form of the leptin receptor [J].
Banks, AS ;
Davis, SM ;
Bates, SH ;
Myers, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (19) :14563-14572
[5]  
Barker Kate, 2006, Dent Update, V33, P270
[6]   Ibandronate: A clinical pharmacological and pharmacokinetic update [J].
Barrett, J ;
Worth, E ;
Bauss, F ;
Epstein, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :951-965
[7]  
Bauss F, 2002, J RHEUMATOL, V29, P990
[8]   Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing [J].
Bauss, F ;
Russell, RGG .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (06) :423-433
[9]  
Bauss Frieder, 2006, Ther Clin Risk Manag, V2, P3
[10]   DEPLETION OF ALVEOLAR MACROPHAGES BY LIPOSOME-ENCAPSULATED DICHLOROMETHYLENE DIPHOSPHONATE [J].
BERG, JT ;
LEE, ST ;
THEPEN, T ;
LEE, CY ;
TSAN, MF .
JOURNAL OF APPLIED PHYSIOLOGY, 1993, 74 (06) :2812-2819